单纯胰岛素强化治疗及联合双胍类药物的疗效比较被引量：1

下载PDF

导出

摘要 49例短病程2型糖尿病住院患者随机分为胰岛素强化治疗组(23例),胰岛素联合二甲双胍组(26例),测定强化治疗2周前后各组患者FPG、Ins、C-P、hsC-RP及75g葡萄糖负荷后2hPG、Ins、C-P。应用稳态模型计算β细胞功能(HOMA-B)和胰岛素抵抗指数(HOMA-IR),同时比较两组治疗前后各指标的变化级治疗费用。结果强化治疗后胰岛素+二甲双胍组相比胰岛素组HOMA-β水平显著升高(P<0.05),HOMA-IR水平显著下降(P<0.05);血糖达标时间显著缩短,胰岛素及治疗费用显著下降(P<0.05)。结论胰岛素联合二甲双胍较单纯胰岛素治疗更能有效改善型糖尿病患者的胰岛β细胞功能,减轻胰岛素抵抗,能明显减少胰岛素用量及治疗费用。

作者徐文华崔刚丁元红

机构地区齐鲁医院日照分院东港医院内分泌科

出处《实用糖尿病杂志》 2011年第2期45-46,共2页 Journal of Practical Diabetology

关键词 2型糖尿病胰岛素二甲双胍胰岛Β细胞功能

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献4

1腾卫平李玉姝郭颖等.高血糖抑制2型糖尿病脂岛素分泌毒性作用的临床研究[J].中国医科大学学报,2009,29:365-368.
2肖新华.葡萄糖耐量异常与微血管并发症[J].世界医学杂志,2004,8(9):1-3. 被引量：7
3Purrello F, Rabuazza AM, Metabolic factors that affect beta cell fundtion and survivel. Diabet Nutr metab 2000;13:84 -91.
4袁彩红,康运凯,王志新.胰岛素敏感性及血浆纤溶系统与肥胖T2DM肾病相关性研究[J].医药论坛杂志,2008,29(4):26-28. 被引量：8

二级参考文献22

1Kuller LH, Velentgas P, Barzilay J, Beauchanp NJ, O'Leary DH. Savage PJ:Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Ar~rioscler Thromb Vasc Biol20:823 -829,2000.
2Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little R1L Wiedmeyer HM, Byrd-Holt DD: Prevalence of Diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care21: 518-524,1999.
3Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW: Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin dependent diabetes mellitus (NIDDM). Muscle Nerve21:?2 -80, 1998.
4Franklin GM, Kalm LB, Bender J, Marshall JA, Hamman RF: Sensory neuropathy in non-insulin-dependent diabetes meUitus. The San Luis Valley Diabetes Study. Am J Epidemioll31: 633-643, 1990.
5Smith AG, Tripp C, Singleton JR: Skin biopsy findings in patients with neuropathy associated with diabetes and impaired glucose tolerance. Neurology 57: 1701-1704,2001.
6Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti IL Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetes Care 24: 683-689, 2001.
7Windebank A, Feldman E: Diabetes and the nervous system. In Neurology and General Medicine. Aminoff M, Fed. Pldladelphia, PA, Churchill Livingstone, 2001,p341-p364.
8Singh R. Barden A. Mori T. Beifin L: Advanced glycation end-products: a review.Diabetologia44:129-146, 2001.
9Cameron NE. Eaton SE, Cotter MA, Tesfaye S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973-1988,2001.
10Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groops L: The metabolic syndrome influences the risk of chronic compfications in patients with type Ⅱ diabetes Diabetologia44:1148-1154, 2001.